论文部分内容阅读
目的:研究WHO新标准下骨髓增生异常综合征(MDS)各型患者血浆nm23-H1蛋白水平的表达,以探讨其表达水平与MDS分型、发展及预后的关系。方法:采用酶联免疫法(ELISA)检测86例不同病期MDS患者血浆中nm23-H1蛋白含量,同时以50例正常健康人作对照。结果:MDS患者RA型、RARS型及5q-综合征血浆nm23-H1蛋白水平与健康对照组相比无显著性差异(P>0.05),RCMD型、RCMD-RS型、RAEB-Ⅰ型、RAEB-Ⅱ型及MDS-U期患者血浆nm23-H1蛋白水平明显高于健康对照组(P<0.05)。结论:nm23-H1蛋白在MDS患者不同病期表达水平不同,其含量与MDS病程的发展及转归有关,同时可以提示疾病的预后。
Objective: To study the expression of nm23-H1 protein in various types of patients with myelodysplastic syndrome (MDS) under the new WHO criteria to investigate the relationship between the expression level of nm23-H1 and the classification, development and prognosis of MDS. Methods: Enzyme linked immunosorbent assay (ELISA) was used to detect the plasma levels of nm23-H1 protein in 86 patients with MDS at different stages of disease. At the same time, 50 normal healthy subjects were used as controls. Results: The plasma level of nm23-H1 in RA patients, RARS patients and patients with 5q-syndrome in MDS patients were not significantly different from those in healthy controls (P> 0.05). RCMD, RCMD-RS, RAEB- The levels of nm23-H1 protein in patients with type-II and MDS-U were significantly higher than those in healthy controls (P <0.05). Conclusion: The expression of nm23-H1 protein in different stages of MDS patients is different. The content of nm23-H1 protein is related to the development and prognosis of MDS. It can also indicate the prognosis of the disease.